ArticlePloS one2025
Gene expression profiling, prognosis, and immune microenvironment of KLF4 in malignancies.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gene expression profiling plays a crucial role in understanding the role of Krüppel-like factor 4 (KLF4) in the prognosis and tumor immune microenvironment of various malignancies. The transcription factor KLF4 plays a crucial role in various cellular processes, including cell differentiation, proliferation, and apoptosis. Genetic alterations and aberrant KLF4 expression have been observed in many malignancies, thus suggesting a potential role as a prognostic marker and therapeutic target. Herein, a systematic analysis of KLF4 genetic alterations revealed the mutation, amplification, and deletion frequencies across different cancer types. The genetic alteration patterns varied across malignancies, thus highlighting the diverse roles of KLF4 in different tumor contexts. Secondly, the prognostic significance of KLF4 expression was assessed in multiple cancers. High expression levels of KLF4 were associated with better clinical outcomes in kidney renal clear cell carcinoma, while low KLF4 expression correlated with a favorable prognosis in certain malignancies. In conclusion, the genetic alterations, dysregulated RNA expression, and prognostic implications of KLF4 in malignancies underscore its significance in cancer biology. The present findings will aid in understanding the role of KLF4 in tumor biology and its association with immune responses. Future investigations should focus on elucidating the functional roles and regulatory mechanisms of KLF4 to further assess its potential as a therapeutic target and predictive biomarker in cancer management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.